Abstract: Disclosed herein is a pharmaceutical composition that includes, based on the total weight of the composition, 5% to 30% of an active pharmaceutical ingredient including an acetone-extracted product and a saccharide compound in a weight ratio of 9:1, 20% to 75% of a solubilizing agent, 5% to 30% of a disintegrating agent, 5% to 30% of a filling agent, 0.1% to 5% of a flow agent, and 0.1% to 5% of a lubricant. The active pharmaceutical ingredient has an average particle size of about 1 ?m to 30 ?m.

Abstract: The present invention provides a method of identifying a viral-host junction sequence from a subject with a hepatocellular carcinoma caused by chronic infection of hepatitis B virus. The viral-host junction sequence has a length of less than 200 bps and comprises a hepatitis B viral genome sequence and a host genome sequence.

Abstract: The present invention provides a chimera nucleic acid obtained from circulatory system for monitoring tumor size. The nucleic acid comprises partial sequence derived from host genome and partial sequence derived from non-host genome. The partial sequence derived from host genome and the partial sequence derived from non-host genome form a chimera junction. The chimera junction is obtained from cell-free nucleic acids and is indicative of tumor size.

Abstract: The present invention provides a chimera nucleic acid obtained from circulatory system for monitoring tumor status. The nucleic acid comprises partial sequence derived from host genome and partial sequence derived from non-host genome. The partial sequence derived from host genome and the partial sequence derived from non-host genome form a chimera junction. The chimera junction is obtained from cell-free nucleic acids and is indicative of disease status.